Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDL-AP3
Discontinued Product
0125 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
说明： Group I mGlu antagonist; also phosphoserine phosphatase inhibitor
化学名： DL-2-Amino-3-phosphonopropionic acid
生物活性 for DL-AP3
DL-AP3 is a competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.
技术数据 for DL-AP3
| 分子量 | 169.07 |
| 公式 | C3H8NO5P |
| 储存 | Store at RT |
| CAS Number | 5652-28-8 |
| PubChem ID | 3857 |
| InChI Key | LBTABPSJONFLPO-UHFFFAOYSA-N |
| Smiles | NC(CP(O)(O)=O)C(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for DL-AP3
参考文献 for DL-AP3
参考文献是支持产品生物活性的出版物。
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Hawkinson et al (1996) The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur.J.Pharmacol. 307 219 PMID: 8832224
Saugstad et al (1995) L-2-Amino-3-phosphonopropionic acid completely antagonizes metabotropic glutamate receptors 1α and 5 in Xenopus oocytes. Eur.J.Pharmacol. 289 395 PMID: 7621916
按标靶查看相关产品
关键词: DL-AP3, DL-AP3 supplier, Phosphoserine, phosphatase, inhibitors, inhibits, Group, I, mGlur, antagonists, Protein, Ser/Thr, Phosphatases, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, 20263-06-3, (Metabotropic), 0125, Tocris Bioscience
1 篇 DL-AP3 的引用文献
引用文献是使用了 Tocris 产品的出版物。 DL-AP3 的部分引用包括：
Vance et al (2015) PAR1-activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors. J Neurosci 35 776 PMID: 25589770
DL-AP3 的评论
目前没有该产品的评论。 Be the first to review DL-AP3 and earn rewards!
Have you used DL-AP3?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.